Chugai Pharmaceutical Co
Chugai Pharmaceutical Co., Ltd., commonly referred to as Chugai, is a leading biopharmaceutical company headquartered in Tokyo, Japan. Established in 1925, Chugai has made significant strides in the pharmaceutical industry, particularly in the fields of oncology, immunology, and renal diseases. The company is renowned for its innovative research and development, focusing on the creation of novel therapeutic agents that address unmet medical needs. With a strong presence in Japan and expanding operations in Europe and the United States, Chugai has positioned itself as a key player in the global biopharmaceutical market. Its core products, including the pioneering monoclonal antibody therapies, are distinguished by their efficacy and safety profiles. Notably, Chugai has achieved remarkable milestones, such as the successful development of groundbreaking treatments that have transformed patient care.
DitchCarbon Score
How does Chugai Pharmaceutical Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Chugai Pharmaceutical Co's score of 50 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Chugai Pharmaceutical Co's reported carbon emissions
In 2023, Chugai Pharmaceutical Co., based in Japan, reported total greenhouse gas emissions of approximately 1,045,000,000 kg CO2e. This figure includes 44,500,000 kg CO2e from Scope 1 emissions, 97,200,000 kg CO2e from Scope 2 emissions, and a significant 1,000,000,000 kg CO2e from Scope 3 emissions. The combined Scope 1 and 2 emissions totalled about 51,800,000 kg CO2e. Chugai has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 emissions by 60% by 2030 from a 2019 baseline. Additionally, the company plans to increase its annual sourcing of renewable electricity from 0% in 2019 to 100% by 2025. For Scope 3 emissions, Chugai targets a reduction of 30% by 2030 from the same 2019 baseline. These targets have been validated by the Science Based Targets initiative (SBTi) and align with the goal of limiting global warming to 1.5°C. Chugai's commitment reflects a proactive approach to addressing climate change within the pharmaceutical industry, demonstrating a clear strategy for emissions reduction and sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 47,300,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 65,500,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Chugai Pharmaceutical Co is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
